Optimising The Management Of Comorbidities In Dementia: Reducing Disparaties And Improving Clinical Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$603,894.00
Summary
Many individuals with dementia also have other chronic medical conditions. This research will help us better understand the comorbidities experienced by people with dementia and the impact these have on clinical outcomes This can lead to the development of consumer-centred management strategies. By ensuring the appropriate, equitable and timely treatment of comorbidities in people with dementia, there is potential to optimise the quality of life and health of people with dementia.
Why Is There An Increased Risk Of Severe Adverse Perinatal Outcomes After The Use Of Clomiphene Citrate For Infertility Treatment?
Funder
National Health and Medical Research Council
Funding Amount
$570,065.00
Summary
Clomiphene citrate (CC) has been a first line treatment for female infertility internationally since the 1960’s. However, safety studies using routine prescribing practices were never performed, and numerous data sources now indicate that CC is associated with major adverse outcomes if the fetus is inadvertently exposed. We are linking prescription data to perinatal outcomes to confirm how CC is associated with adverse events so as to inform prescriber and practice change.
Optimising Medicine Regimens For People With Dementia: Maintaining Function, Maximising Quality Of Life And Preventing Adverse Events
Funder
National Health and Medical Research Council
Funding Amount
$715,017.00
Summary
I am a pharmacist based at Monash University. My expanding research team generates and applies evidence to optimise medicine regimens for people with dementia. My research assesses the risks and benefits of medicines for dementia and other health conditions. I will also focus on research training and capacity building. My research ensures people with dementia and their clinicians are equipped with the best evidence to inform medicines management decisions to optimise health outcomes.
Optimising Pharmaceutical Care For People With Dementia In Acute Care Settings
Funder
National Health and Medical Research Council
Funding Amount
$719,637.00
Summary
Delivering appropriate acute care services for people with dementia is a major healthcare challenge in Australia. People with dementia do not receive appropriate care in hospitals and are more likely to experience worse clinical outcomes compared to people without dementia. This proposal will establish the first large-scale multi-centre cohort of inpatients with dementia, to systematically investigate the impact of hospitalisation on prescribing, clinical and patient-centred outcomes.
Optimising Value And Equity In Access To Prescribed Medicines
Funder
National Health and Medical Research Council
Funding Amount
$371,052.00
Summary
The strong opposition to the Federal government’s proposed increase in out-of-pocket healthcare costs in the 2014 budget demonstrates the significance of value-for-money healthcare to the Australian public. Using information from Canada and Australia, this study will help patients, regardless of socioeconomic status, to access the medicines they need in a way that is affordable for individuals and governments, resulting in wise and fair medicine use within the Australian healthcare system.
Developing A Framework To Evaluate Low Value Prescribing In The Australian Health Care Setting
Funder
National Health and Medical Research Council
Funding Amount
$124,608.00
Summary
The aim of this project is to develop a framework to evaluate the quality of prescribing in Australia using routinely collected administrative health data. Given growing concerns regarding the quality of prescribing of psychotropic medicines and opioids, these medicines will be e focus of the study. Patterns, quality markers and health and financial consequences of poor prescribing will be assessed.
Large Scale Data For Common, Potentially Modifiable Causes Of Morbidity And Mortality
Funder
National Health and Medical Research Council
Funding Amount
$761,656.00
Summary
Large-scale cohort studies, that follow the health of a large proportion of the general population over time, have enormous potential to inform disease prevention and the optimal use of health services. The planned research will use large scale cohort study data, linked to data on health outcomes and use of health services to provide much needed evidence on Indigenous health, safety of medicines and healthy ageing.
Combating Escalating Harms Associated With Pharmaceutical Opioid Use
Funder
National Health and Medical Research Council
Funding Amount
$925,767.00
Summary
Increases in opioid use have been accompanied by increased opioid harms. But there is a lack of population-level evidence about drivers of long-term prescribed opioid use, dependence, overdose and other harms. Using linked data, we will fill these gaps using a cohort of all people in NSW prescribed opioids since 2002, linked to datasets containing information on health, social and health service utilisation, that will permit a comprehensive assessment of the risks of all prescribed opioids.
Medicine-associated Dementia And Cognitive Impairment: Identifying The Problem, Reducing The Harm
Funder
National Health and Medical Research Council
Funding Amount
$513,116.00
Summary
Several studies have shown an association between use of anticholinergic or sedative medicines and increased risk of dementia. Questions remain about whether these medicines cause dementia (or are just used by people already at risk), whether or not cognitive function improves if the medicines are stopped or if the dose is reduced, and the characteristics of patients most likely to use these medicines. This program of research aims to answer these questions.
Big Data To Real World Evidence: Informing Pharmaceutical Policy Decisions Around Targeted Cancer Medicines
Funder
National Health and Medical Research Council
Funding Amount
$86,073.00
Summary
The proposed research will examine the use of targeted cancer therapies in Australia. At present there is little evidence around how these medications are being used in the real world, medical services their use requires, and costs associated with their use. Analysing linked, routinely collected health data, this project will generate new scientific and methodological knowledge about the use and impact of targeted cancer therapies available via publicly funded access programs in Australia.